Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Saturday, August 29, 2015
Did you have concerns regarding the safety and quality of the Indian Sofosbuvir?
I have no concerns about Indian generics generally. In all areas of the world, there are issues of quality control and there are good companies and not-so-good companies. India has some of the largest and best pharmaceutical manufacturers in the world. I actually get really angry when doctors in the UK or the US refuse to prescribe life-saving drugs because they are made in India. It reeks of racism or post-colonial arrogance! Did you know that I have had dozens of emails from people in the UK with hep C who have tried to get a prescription for Indian Sofosbuvir and not one doctor in all of the UK would write it for these people. But I have had two prescriptions for Indian Sofosbuvir from the UK. One was from a doctor who had hep C himself and the other was from a doctor whose best friend had hep C. None other than that! It astounds me. Tens of thousands of people in the UK are suffering and dying simply because their GPs refuse to write them a prescription for Indian generic medicines!
“Delay in access may further challenge our ability to cure hepatitis C in this country,” Joseph K. Lim, MD, associate professor of medicine and director of the Yale Viral Hepatitis Program at Yale University, said in a press release. “Some patients are told they must wait until they have advanced liver disease before they can undergo potentially curative treatment. We hope these data may help inform national policy discussions on promoting more rational, patient-centered approaches to HCV treatment access.”
“This is the first study to our knowledge assessing real-world access to interferon-free [direct-acting antiviral] regimens in established cohorts of patients with chronic HCV seeking antiviral therapy,” the researchers wrote. “These results contribute to the limited data available addressing proportion of patients successfully obtaining drug authorization through public and private insurance carriers, time to approval, and predictors for approval. … Further studies are warranted to investigate the impact of evolving drug authorization policies by Medicare/Medicaid and private payers on access to curative HCV therapies such as [sofosbuvir and ledipasvir].” – by Melinda Stevens.
Do A, et al. PLoS One. 2015;doi:10.1371/journal.pone.0135645.
Friday, August 28, 2015
Children as young as 10 are getting tattoos illegally, without realising they risk catching HIV and hepatitis
A worrying number of youngsters are visiting illegal tattoo parlours, unaware it is against the law for them to be inked before they are 18.
And half admitted to being unaware of the risk of infection from HIV and hepatitis.
Thursday, August 27, 2015
VBI Vaccines (Nasdaq: VBIV) has secured $6.29 million from a variety of venture capital investors, including new investor RTW Investments, with participation from ARCH Venture Partners and Perceptive Advisors.
Under the terms, VBI sold 3 million shares of stock at approximately $2 a share, resulting in the raise.
The tablet drug Harvoni, developed by U.S.-based Gilead Sciences Inc., is expected to revolutionize the treatment of patients with hepatitis C genotype 1, which accounts for about 70 percent of all hepatitis C patients in Japan.
A daily dose of one pill set at ¥80,171 will starting Monday be covered by the insurance, limiting the patient cost to about ¥20,000 a month. Read more.... Read our Hepatitis C Around the World on Japan: go here....
The finding, published Aug. 27 in PLOS ONE, identifies a new barrier to caring for patients with this severe condition.
Prior to the FDA approval of novel antiviral therapies for HCV in 2014, treatment options for patients were limited, requiring weekly injections of interferon-based therapy that caused severe side effects. The new regimens revolutionized treatment and offered patients an oral therapy with cure rates exceeding 90%. However, the high cost of care led insurers to impose new restrictions on drug authorization. Read more....
Wednesday, August 26, 2015
An estimated 3.2 million adults are chronically infected with hepatitis C while an estimated 20,000 people die from the serious liver ailment every year, including many military veterans.
The New York Times reported on Tuesday that a group of experts from the Public Health Service and President Obama’s Advisory Council on H.I.V./AIDS wrote a letter to the White House complaining that restrictions on the use of these drugs by many states are inconsistent with prudent and sound medical practices. Read more....